Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

167.55 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

56 57 Next >

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

September 25, 2023

From Biogen Inc.

Via GlobeNewswire

California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims ↗

September 22, 2023

California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI) and RealOptions Obria, for making unsupported claims about reversing...

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest ↗

September 20, 2023

Via Benzinga

$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

September 15, 2023

Via Benzinga

Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy? ↗

September 09, 2023

Buying a biotech is a good move, but it might not be enough to entice investors.

Via The Motley Fool

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

September 04, 2023

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest ↗

September 01, 2023

Via Benzinga

Analyst Ratings for Biogen ↗

August 29, 2023

Via Benzinga

7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth ↗

September 07, 2023

Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners.

Via InvestorPlace

Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst ↗

September 06, 2023

B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a

Via Benzinga

3 Healthcare Stocks to Sell in September Before They Crash & Burn ↗

September 06, 2023

The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.

Via InvestorPlace

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For ↗

September 06, 2023

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...

Via Benzinga

Biogen Appoints Jane Grogan as Head of Research

September 06, 2023

From Biogen Inc.

Via GlobeNewswire

Better Buy: Biogen vs. Eli Lilly ↗

August 29, 2023

This battle of biotech giants has a clear winner.

Via The Motley Fool

If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today ↗

August 14, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

The 3 Best Biotech Stocks to Buy Now: September 2023 ↗

September 04, 2023

With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.

Via InvestorPlace

Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment ↗

August 31, 2023

The company is now focusing on its launch in postpartum depression.

Via Investor's Business Daily

Looking Into Biogen's Recent Short Interest ↗

August 08, 2023

Via Benzinga

The 7 Most Promising Momentum Stocks to Own Now ↗

August 31, 2023

These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.

Via InvestorPlace

The 3 Most Promising Pharma Stocks to Own Now ↗

August 30, 2023

A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.

Via InvestorPlace

Wall Street Thinks This Tiny Biotech Company Could Soar Soon ↗

August 28, 2023

An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.

Via The Motley Fool

Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock ↗

August 24, 2023

Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5%

Via InvestorPlace

Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month? ↗

August 24, 2023

The pharmaceutical company's growth prospects have taken a big hit.

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

August 17, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Why Shares of Sage Therapeutics Slumped This Week ↗

August 11, 2023

The company got bad news from the FDA and saw increased losses.

Via The Motley Fool

Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around? ↗

August 10, 2023

The company's rare disease portfolio may soon get an upgrade.

Via The Motley Fool

With an Acquisition on the Way, Is Biogen Stock a Buy? ↗

August 09, 2023

Can the biotech finally get back in the good graces of investors?

Via The Motley Fool

Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy? ↗

August 09, 2023

Lilly shares surged 15% in one day to a record high. Here's what you should know.

Via Investor's Business Daily

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)

August 08, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Biogen Idec (NQ:BIIB)

All News about Biogen Idec

Starting at $3.75/week.

Subscribe Today